{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "60001013",
    "licUnit": "1",
    "validDate": "2031-03-04 00:00:00.000",
    "issueDate": "2025-06-06 00:00:00.000",
    "oriIssueDate": "2016-03-04",
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA06000101306",
    "prodNameC": "保疾伏",
    "prodNameE": "OPDIVO (nivolumab) Injection 10mg\/mL",
    "indicationsName": [
        "１、無法切除或轉移性黑色素瘤：單一療法或併用ipilimumab適用於治療無法切除或轉移性黑色素瘤病人。\n２、黑色素瘤之輔助治療：適用於黑色素瘤侵犯至淋巴結或已轉移且曾進行完全切除性手術之病人的輔助治療。\n３、可切除之非小細胞肺癌的術前輔助治療：併用含鉑化學治療適用於可切除（腫瘤≧4公分或淋巴結陽性）且不具EGFR或ALK腫瘤基因異常之非小細胞肺癌(NSCLC)成年病人的術前輔助治療。\n４、非小細胞肺癌：(1)併用ipilimumab適用於帶有PD-L1 (≧1%)且不具EGFR或ALK腫瘤基因異常的轉移性或復發性非小細胞肺癌(NSCLC)成年病人的第一線治療。(2)併用ipilimumab及2個週期含鉑化學治療適用於不具EGFR或ALK腫瘤基因異常的轉移性或復發性非小細胞肺癌(NSCLC)成年病人的第一線治療。(3)併用 carboplatin、paclitaxel及 bevacizumab適用於不具EGFR或 ALK腫瘤基因異常的轉移性或復發性非鱗狀非小細胞肺癌(non-squamous NSCLC) 成年病人的第一線治療。(4)適用於接受含鉑化學治療時或之後疾病惡化的晚期非小細胞肺癌(NSCLC)病人，病人若具有EGFR或ALK腫瘤基因異常者，則須經EGFR或ALK抑制劑治療後出現疾病惡化現象。\n５、惡性肋膜間皮瘤：併用ipilimumab適用於無法切除之惡性肋膜間皮瘤成人病人的第一線治療。\n６、腎細胞癌：(1)適用於先前經抗血管新生療法治療(anti-angiogenic therapy)的晚期腎細胞癌病人。(2)併用ipilimumab可用於治療中度\/重度風險(intermediate\/poor-risk)先前未曾接受治療的晚期腎細胞癌病人。(3)併用cabozantinib適用於未曾接受治療的晚期腎細胞癌病人。\n７、頭頸部鱗狀細胞癌：適用於接受含鉑化學治療時或之後疾病惡化的復發或轉移性頭頸部鱗狀細胞癌(SCCHN)病人。\n８、典型何杰金氏淋巴瘤：適用於經下列方式治療後復發或惡化的典型何杰金氏淋巴瘤成人病人：(1)接受自體造血幹細胞移植(HSCT)與brentuximab vedotin，或(2)接受3種或3種以上全身性療法，包括自體造血幹細胞移植(HSCT)。\n本項適應症係依據客觀反應率(objective response rate)獲得加速核准。適應症的持續核准須要後續確認性試驗(confirmatory trial)證明確實達到臨床效益。\n９、泌尿道上皮癌：(1)併用cisplatin和gemcitabine適用於無法切除或轉移性泌尿道上皮癌成人病人的第一線治療。(2)適用於治療接受含鉑療法期間或之後惡化的局部晚期無法切除或轉移性泌尿道上皮癌病人。本項適應症係依據腫瘤反應率(tumor response rate)及治療反應持續時間(duration of response)獲得加速核准。適應症的持續核准須要後續確認性試驗(confirmatory trial)證明確實達到臨床效益。(3)適用於在接受根治性切除術後，有高度復發風險的泌尿道上皮癌病人輔助治療。\n１０、胃癌、胃食道癌或食道腺癌：(1)併用fluoropyrimidine及含鉑化學治療適用於治療晚期或轉移性，且不具有HER2過度表現的胃癌或胃食道癌(Gastroesophageal Junction, GEJ)或食道腺癌的病人。(2)適用於治療先前經兩種或兩種以上化學治療的晚期或復發性胃癌或胃食道癌的病人。\n１１、肝細胞癌：(1) 併用ipilimumab適用於無法切除或轉移性的肝細胞癌(HCC)成人病人的第一線治療。(2) 併用ipilimumab適用於治療先前曾接受sorafenib治療的肝細胞癌(HCC)成人病人。\n１２、轉移性大腸直腸癌：(1)併用ipilimumab適用於無法手術切除或轉移性高度微衛星不穩定性(MSI-H)或錯誤配對修復缺陷(dMMR)的大腸直腸癌(CRC)成人病人。(2)單一藥物適用於接受fluoropyrimidine、oxaliplatin和irinotecan治療後疾病惡化之轉移性高度微衛星不穩定性(MSI-H)或錯誤配對修復缺陷(dMMR)的大腸直腸癌(CRC)成人病人。\n１３、食道鱗狀細胞癌：(1)併用含fluoropyrimidine及含鉑的化學治療適用於晚期或轉移性食道鱗狀細胞癌(ESCC)病人的第一線治療。(2)併用ipilimumab適用於晚期或轉移性食道鱗狀細胞癌(ESCC)病人的第一線治療。(3)適用於曾接受合併含鉑及fluoropyrimidine 化學治療之後惡化的無法切除晚期或復發性食道鱗狀細胞癌(esophageal squamous cell carcinoma)病人。\n１４、食道癌或胃食道癌切除的輔助治療：適用於曾接受術前同步化學與放射治療(neoadjuvant concurrent chemoradiotherapy)與手術完全切除，經病理檢查確認切除組織仍殘留腫瘤之食道癌或胃食道癌病人的輔助治療。"
    ],
    "does": "2270",
    "packageUnit": [
        {
            "packageSpec": "100支以下",
            "packageUnit": "03"
        },
        {
            "packageSpec": "12毫升",
            "packageUnit": "L2"
        },
        {
            "packageSpec": "100支以下",
            "packageUnit": "03"
        },
        {
            "packageSpec": "100支以下",
            "packageUnit": "03"
        },
        {
            "packageSpec": "10毫升",
            "packageUnit": "L2"
        },
        {
            "packageSpec": "2毫升",
            "packageUnit": "L2"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": null,
    "mainCategory": null,
    "drBaseId": "513E5D30-65F4-4423-8005-14D8212E0E73",
    "subCategory": [],
    "ingredientsDesc": [
        "Nivolumab"
    ],
    "restraintItemsCode": [
        "02 輸 入",
        "07 新藥監視",
        "51 免除銜接性臨床試驗",
        "68 成品已完成元素不純物評估(Option 3)"
    ],
    "applicantName": "台灣小野藥品工業股份有限公司",
    "applicantAddr": "臺北市信義區忠孝東路5段68號12樓",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": null,
    "mdKind": [],
    "monitorDate": "2021-03-04",
    "licidNew": null,
    "licidOld": null,
    "manuImportDesc": "廠商未登錄資料",
    "licManuImport": "2",
    "factoryDtoList": [
        {
            "id": "3C109BEF-C6B5-450F-8036-2641CB5C603F",
            "factoryCode": "1",
            "factoryName": "ONO PHARMACEUTICAL CO., LTD. FUJIYAMA PLANT",
            "factoryAddr": "5221-1, AZAHIGASHISHIMOGUMI, KITAYAMA, FUJINOMIYA-SHI, SHIZUOKA, JAPAN",
            "factoryCompanyAddr": null,
            "countryCode": "JP",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "FJP0576000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "6F583E05-CFDE-4670-A260-2315334DCF0D",
            "factoryCode": "1",
            "factoryName": "Ono Pharmaceutical Co., Ltd. Yamaguchi Plant",
            "factoryAddr": "3-45, Sayama, Yamaguchi-shi, Yamaguchi, Japan",
            "factoryCompanyAddr": "",
            "countryCode": "JP",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "FJP1067000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "FE8CD415-0D97-415C-9241-06C0C49B3110",
            "factoryCode": "2",
            "factoryName": "Swords Laboratories Unlimited Company t\/a Bistrol-Myers Squibb Cruiserath Biologics",
            "factoryAddr": "Cruiserath Road, Mulhuddart, Dublin 15, D15 H6EF, Ireland",
            "factoryCompanyAddr": "",
            "countryCode": "IE",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FIE0133000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013005600",
            "ingredientsName": "Nivolumab",
            "ingredientsDesc": "Nivolumab",
            "concentDesc": "",
            "concent": "10.000000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "3",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FF01"
        }
    ],
    "udiInfoList": [],
    "licBaseId": "B2A80939-7C0A-4DE0-A870-65DC570A5DB8"
}